Concepedia

Scott E. Lazerwith

SE

Statistics

Publications

17

Citations

1.9K

H-Index

15

Active since

1997

Affiliations

Gilead Sciences (United States)(Current)

Pfizer (United States)

Scripps Research Institute

Harvard University

Torrey Pines Institute For Molecular Studies

Scott E. Lazerwith is an author at Gilead Sciences (United States) specializing in drug discovery, antiviral therapy, and molecular virology.

Publications per year

1997–2022

17

Publications

17

Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

Kay Ahn, Douglas S. Johnson, Mauro Mileni et al. · Chemistry & Biology · 2009 · 442 citations · Full text

, , +13

Clinical targeting of HIV capsid protein with a long-acting small molecule

John O. Link, Martin S. Rhee, Winston C. Tse et al. · Nature · 2020 · 421 citations · Full text

, , +12

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Manuel Tsiang, G.S. Jones, Joshua Goldsmith et al. · Antimicrobial Agents and Chemotherapy · 2016 · 283 citations · Full text

, , +17

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor

Douglas S. Johnson, Cory M. Stiff, Scott E. Lazerwith et al. · ACS Medicinal Chemistry Letters · 2010 · 200 citations · Full text

, , +16

Bio-orthogonal Affinity Purification of Direct Kinase Substrates

Jasmina J. Allen, Scott E. Lazerwith, Kevan M. Shokat · Journal of the American Chemical Society · 2005 · 101 citations · Full text

, , +17

1–5 of 17